ETFChannel.com
BHVN Description — Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical is a clinical-stage biopharmaceutical company with a portfolio of late-stage product candidates targeting central nervous system diseases. Co.'s product candidates are small molecules and based on three mechanistic platforms-calcitonin gene-related peptide (CGRP) receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Co. is developing rimegepant as an orally available, selective and small molecule CGRP receptor antagonist for the acute and preventive treatment of migraine. Co. is developing troriluzole and BHV-0223, acting as glutamate transporter modulators, while BHV-5000 is an antagonist of the glutamate N-methyl-D-aspartate receptor.

Company Name: 
Biohaven Pharmaceutical Holding Co Ltd
Website: 
www.biohavenpharma.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BHVN: 
29
Total Market Value Held by ETFs: 
$546,992,617.86
Total Market Capitalization: 
$8,894,000,000
% of Market Cap. Held by ETFs: 
6.15%
 ETF   BHVN Weight   BHVN Amount 
 IWM   0.25%   $168,104,617         
 VXF   0.09%   $109,045,424         
 IBB   0.56%   $62,605,986         
 XBI   0.85%   $61,496,286         
 IWO   0.33%   $39,957,009         
 IWN   0.17%   $26,482,922         
 VHT   0.12%   $23,302,193         
 VTWO   0.25%   $16,455,892         
 ITOT   0.02%   $7,665,287         
 VTWG   0.32%   $4,857,472         
List of all 29 ETFs holding BHVN »
Quotes delayed 20 minutes

Strong Buy (3.64 out of 4)
59th percentile
(ranked higher than approx. 59% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding BHVN | Biohaven Pharmaceutical Holding Co Ltd | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.